Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 4;16(7):e63842.
doi: 10.7759/cureus.63842. eCollection 2024 Jul.

Complications and Mortality Rate of Vagus Nerve Stimulation for Drug-Resistant Epilepsy

Yitao Ma  1 , Nicholas Lehman  1 , Robert Crutcher  2 , William Young  1 , David Horvat  3
Affiliations

Complications and Mortality Rate of Vagus Nerve Stimulation for Drug-Resistant Epilepsy

Yitao Ma et al. Cureus. .

Abstract

Objective: The goal of this study is to evaluate the complications and mortality associated with vagus nerve stimulation (VNS).

Methods: We retrospectively reviewed medical records of patients who underwent VNS implantation for the treatment of drug-resistant epilepsy (DRE) between 2000 and 2023. The mean follow-up time was 10.6 years, ranging from three months to 22 years.

Results: In total, 55 adult and pediatric patients received VNS therapy with 117 procedures performed over 23 years. The most common early complications were hoarseness and cough which were reported in eight adult patients (6.8%). Four children with intellectual disability (ID) had infection (3.4%), eight patients had lead breakage (6.8%), and two had device migration (1.7%). Four of all patients (7.3%) demonstrated late complications due to chronic nerve stimulation including vocal cord dysfunction, late-onset severe AV block, and obstructive sleep apnea (OSA). Three patients (5.5%) had VNS deactivated permanently due to complications and/or lack of efficacy. Two patients died from probable sudden unexpected death in epilepsy (SUDEP) with an incidence of 3.4/1000 person-years.

Conclusions: VNS therapy is safe over long-term follow-up but not without risks. Most post-operative complications are minor and transient for adults. Children with ID tend to have infection and device migration. Late-onset cardiac complications and OSA can develop in some patients during VNS therapy and should not be overlooked. The SUDEP rate may decrease with VNS therapy over time.

Keywords: av block; complications; drug-resistant epilepsy; sleep apnea; sudep (sudden unexplained death in epilepsy); vagus nerve stimulation.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent was obtained or waived by all participants in this study. IRB Committee of Walter Reed National Military Medical Center issued approval WRNMMC-EDO-2023-1129. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Uniformed Services University of the Health Sciences, Department Health Agency, Department of Defense or the U.S. Government. .

References

    1. Cost-benefit of vagus nerve stimulation for refractory epilepsy. Boon P, Vonck K, D'Have M, O'Connor S, Vandekerckhove T, De Reuck J. https://www.ncbi.nlm.nih.gov/pubmed/10674145. Acta Neurol Belg. 1999;99:275–280. - PubMed
    1. Health technology assessment report on vagus nerve stimulation in drug-resistant epilepsy. Marras CE, Colicchio G, De Palma L, et al. Int J Environ Res Public Health. 2020;17 - PMC - PubMed
    1. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: a critical review. Toffa DH, Touma L, El Meskine T, Bouthillier A, Nguyen DK. Seizure. 2020;83:104–123. - PubMed
    1. Vagus nerve stimulation for the treatment of epilepsy. González HF, Yengo-Kahn A, Englot DJ. Neurosurg Clin N Am. 2019;30:219–230. - PMC - PubMed
    1. Late-onset periodic bradycardia during vagus nerve stimulation in a pediatric patient. A new case and review of the literature. Cantarín-Extremera V, Ruíz-Falcó-Rojas ML, Tamaríz-Martel-Moreno A, García-Fernández M, Duat-Rodriguez A, Rivero-Martín B. Eur J Paediatr Neurol. 2016;20:678–683. - PubMed

LinkOut - more resources